Twenty-one years at the Uniting Medically Supervised Injecting Centre, Sydney: addressing the remaining questions.

Day CA, Salmon A, Jauncey M, Bartlett M, Roxburgh A

Commentary on Skulberg et al.: Naloxone administration-finding the balance.

Jauncey M, Bartlett M, Roxburgh A

Assessing Drug Consumption Rooms and Longer Term (5 Year) Impacts on Community and Clients.

Tran V, Reid SE, Roxburgh A, Day CA

COVID-19

New Australian guidelines for the treatment of alcohol problems: an overview of recommendations.

Haber PS, Riordan BC, Winter DT, Barrett L, Saunders J, Hides L, Gullo M, Manning V, Day CA, Bonomo Y, Burns L, Assan R, Curry K, Mooney-Somers J, Demirkol A, Monds L, McDonough M, Baillie AJ, Clark P, Ritter A, Quinn C, Cunningham J, Lintzeris N, Rombouts S, Savic M, Norman A, Reid S, Hutchinson D, Zheng C, Iese Y, Black N, Draper B, Ridley N, Gowing L, Stapinski L, Taye B, Lancaster K, Stjepanović D, Kay-Lambkin F, Jamshidi N, Lubman D, Pastor A, White N, Wilson S, Jaworski AL, Memedovic S, Logge W, Mills K, Seear K, Freeburn B, Lea T, Withall A, Marel C, Boffa J, Roxburgh A, Purcell-Khodr G, Doyle M, Conigrave K, Teesson M, Butler K, Connor J, Morley KM

Alcohol + Other Drugs

Trends in MDMA-related mortality across four countries.

Roxburgh A, Sam B, Kriikku P, Mounteney J, Castanera A, Dias M, Giraudon I

Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia.

Roxburgh A, Jauncey M, Day C, Bartlett M, Cogger S, Dietze P, Nielsen S, Latimer J, Clark N

COVID-19 Injecting Drug Use